dsm-firmenich achieves regulatory clearance in China for two HMO ingredients for early life nutrition

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

dsm-firmenich-China

More Like This

PR Newswire associated0

Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

PR Newswire associated0

Wyeth Becomes the First Multinational Company to Launch an HMO Growing-Up Infant Formula in China

PR Newswire associated0

Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations

PR Newswire associated0

New Illuma Growing-up Infant Formula Now Available throughout China

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)

Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods

PR Newswire associated0

dsm-firmenich takes strategic actions to strengthen its position as a leading creation and innovation partner in Nutrition, Health and Beauty

PR Newswire associated0

dsm-firmenich to sell stake in Feed Enzymes Alliance to its partner Novonesis for €1.5 billion

PR Newswire associated0

dsm-firmenich completes the divestiture of its Jiangshan Vitamin C plant in China